Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-03-04 @ 10:24 PM
Study NCT ID:
NCT07147205
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-08-29
First Post:
2025-08-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Meaning-centered Group Psychotherapy in Integrative Medicine
Sponsor:
M.D. Anderson Cancer Center
Organization:
Study Overview
Official Title:
Evaluation of Meaning-centered Group Psychotherapy in Integrative Medicine
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To learn more about your experience participating in a virtual Meaning-Centered Psychotherapy group.
Detailed Description:
Primary Objectives
The objectives are to describe the characteristics and outcomes of participants who attend at least one session of MCGP:
1. Describe demographic, clinical characteristics, reasons for referral, and IMC utilization data for participants who attend MCGP.
2. Examine anxiety, depression, quality of life, meaning in life, and fear of cancer recurrence before and after participation in MCGP.
3. Describe satisfaction and qualitative feedback from group participants, including perceived effectiveness and outcomes, experiences participating in the group virtually, and reactions to specific elements of the therapy modified for cancer survivors, length of group (90 minutes), and the nature of a closed group within the IMC.
Secondary Objectives
4. Examine whether demographic, clinical, or symptoms-based (pre) measures are associated with number of MCGP sessions attended.
5. Examine whether number of sessions attended is associated with change in outcome measures.
The objectives are to describe the characteristics and outcomes of participants who attend at least one session of MCGP:
1. Describe demographic, clinical characteristics, reasons for referral, and IMC utilization data for participants who attend MCGP.
2. Examine anxiety, depression, quality of life, meaning in life, and fear of cancer recurrence before and after participation in MCGP.
3. Describe satisfaction and qualitative feedback from group participants, including perceived effectiveness and outcomes, experiences participating in the group virtually, and reactions to specific elements of the therapy modified for cancer survivors, length of group (90 minutes), and the nature of a closed group within the IMC.
Secondary Objectives
4. Examine whether demographic, clinical, or symptoms-based (pre) measures are associated with number of MCGP sessions attended.
5. Examine whether number of sessions attended is associated with change in outcome measures.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| NCI-2025-06343 | OTHER | NCI-CTRP Clinical Registry | View |